Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Kiniksa Pharmaceuticals International PLC maintains a gross margin of 88.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.28%, while the net margin is 10.19%. These profitability ratios, combined with a Return on Equity (ROE) of 7.39%, provide a clear picture of how effectively KNSA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, KNSA competes directly with industry leaders such as ARQT and XENE. With a market capitalization of $3.29B, it holds a leading position in the sector. When comparing efficiency, KNSA's gross margin of 88.80% stands against ARQT's 91.25% and XENE's 100.00%. Such benchmarking helps identify whether Kiniksa Pharmaceuticals International PLC is trading at a premium or discount relative to its financial performance.
